A
summary of the accrued expenses as of September 30, 2022 and March 31, 2022 is as follows (in thousands):
SUMMARY OF ACCRUED EXPENSES
| | |
September 30, 2022 | | |
March 31, 2022 | |
| Research and development | |
$ | 515 | | |
$ | 1,006 | |
| Professional fees | |
| 240 | | |
| 442 | |
| Employee salaries and benefits | |
| 620 | | |
| 409 | |
| Accrual for contingent liabilities (Note 11) | |
| 2,515 | | |
| 2,435 | |
| Accrued Circassia Settlement (Note 9) | |
| 3,500 | | |
| 2,500 | |
| Accrued NitricGen agreement (Note 11) | |
| 1,500 | | |
| 1,500 | |
| Other | |
| 44 | | |
| 82 | |
| Total short-term accrued expenses | |
$ | 8,934 | | |
$ | 8,374 | |
| | |
| | | |
| | |
| Accrued Circassia Settlement payments – long term (Note 9) | |
$ | 4,500 | | |
$ | 8,000 | |
| Total other long-term liabilities | |
$ | 4,500 | | |
$ | 8,000 | |
|